Dr Lal Pathlabs (LALPATHLAB)

FairStock Score: 62/100 — STEADY

Score breakdown: P/E: 0/3 · ROCE: 2/2 · Growth: 1/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Mr. Market wants ₹1,916.30 for Dr Lal Pathlabs, a ₹32,054 Cr healthcare service provider. Graham taught me to demand a margin of safety, and here the numbers are sobering: book value is ₹150.21, P/B is 12.76, Graham Number is ₹303.93, and the margin of safety is -360.60%. A DCF intrinsic value of ₹408.93 tells me the stock is priced for a lot of future success. The 52-week range is ₹1,272.60–₹2,035.00, so we are near the upper end. Yet the business quality is real. ROE is 24.32%, ROCE 28.88%, and debt/equity is only 0.08. Piotroski F-score is 8/9, and Altman Z-score is 7.88, which points to financial strength. Sales grew 19.09%, profit grew 28.31%, and the latest quarter delivered ₹660 Cr of sales and ₹91 Cr of net profit. Five-year revenue CAGR is 13.10%, FCF is ₹266 Cr, dividend yield is 1.02%, and promoters hold 53.21%. That combination suggests a durable, high-return healthcare compounder with a moat in its returns on capital and balance-sheet discipline. However, at P/E 59.16, and PEG 3.14, I would be paying a premium price for good growth. EV/EBITDA of -48.64 also looks anomalous and needs caution. FairStock Score is 62/100, STEADY. I would classify it as a Stalwart: an excellent business, but not a bargain. I would wait for either a lower price or faster earnings to catch up. Watch, don't chase.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer